Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

boiron - croton tiglium 5ch 1 % - pillules - 5ch - croton tiglium 5ch 1 %

Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

boiron - croton tiglium 9ch 1 % - pillules - 9ch - croton tiglium 9ch 1 %

Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

boiron - croton tiglium 30k 1 % - pillules - 30k - croton tiglium 30k 1 %

Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

boiron - croton tiglium 200k 1 % - pillules in single-dose container - 200k - croton tiglium 200k 1 %

Stati Uniti - Ingliż - NLM (National Library of Medicine)

wyeth pharmaceuticals llc, a subsidiary of pfizer inc. - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - protonix for delayed-release oral suspension and protonix delayed-release tablets are indicated for: protonix is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (ee). for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of protonix may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. protonix is indicated for maintenance of healing of ee and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. protonix is indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison (ze) syndrome. risk summary available data from published observational studies did not demonstrate an association of major malformations or other adverse pregnancy outcomes with pa

Stati Uniti - Ingliż - NLM (National Library of Medicine)

avera mckennan hospital - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 40 mg - protonix for delayed-release oral suspension and protonix delayed-release tablets are indicated for: protonix is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of protonix may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. protonix is indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. protonix is indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison syndrome. protonix is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole. hypersensitivity reac

Stati Uniti - Ingliż - NLM (National Library of Medicine)

washington homeopathic products - croton - to relieve the symptoms of poison ivy. indications: croton   poison ivy if symptoms persist/worsen or if pregnant/nursing, stop use and consult your practitioner.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

washington homeopathic products - croton - to relieve the symptoms of poison ivy. indications:  croton   poison ivy if symptoms persist/worsen or if pregnant/nursing, consult your practitioner.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

cardinal health 107, llc - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - protonix for delayed-release oral suspension and protonix delayed-release tablets are indicated for: protonix is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (ee). for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of protonix may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. protonix is indicated for maintenance of healing of ee and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. protonix is indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison (ze) syndrome. risk summary available data from published observational studies did not demonstrate an association of major malformations or other adverse pregnancy outcomes with pa

Stati Uniti - Ingliż - NLM (National Library of Medicine)

redpharm drug, inc. - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - protonix is a proton pump inhibitor (ppi) indicated for the following: short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease (gerd) ( 1.1) maintenance of healing of erosive esophagitis ( 1.2) pathological hypersecretory conditions including zollinger-ellison (ze) syndrome ( 1.3) protonix for delayed-release oral suspension and protonix delayed-release tablets are indicated for: protonix is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (ee). for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of protonix may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. protonix is indicated for maintenance of healing of ee and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not